[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"enlarged-heart\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:enlarged-heart":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100462763","phase-2-sodium-glucose-co-transporter-2-sglt2-and-stemi-100462763",false,"NCT05305911","Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI","Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).","Inclusion Criteria:\n\n* Patients with their first STEMI (\\>18 years) who underwent successful primary PCI and able to give informed consent\n* At least mild LV dysfunction (LVEF \\\u003C 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI\n* Infarct size that is \\> 10% of LV mass\n* The presence of MVO that is \\> 10% of infarct size\n\nExclusion Criteria:\n\n* Contraindication to cardiac MRI\n* Life expectancy \\\u003C 1 year\n* Previous CABG or Valve Surgery\n* Previous STEMI\n* Pregnant or planning to become pregnant or lactating women\n* Cardiogenic shock (not resolved)\n* Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)\n* GFR\\\u003C30 ml\u002Fmin\u002F1.73m2 or end-stage renal disease on dialysis\n* Type 1 diabetes mellitus or history of diabetic ketoacidosis\n* Type I or II diabetes with insulin use\n* Prior intolerance of SGLT2 inhibitors\n* Current use of SGLT2 inhibitors (randomized patients only)\n* Contraindications to gadolinium","ALL","18 Years","75 Years",{"count":20,"type":21},81,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.",[27,28],"Heart Attack","Enlarged Heart",[30,31],"Dapagliflozin","Sodium Glucose Co-Transporter 2","RECRUITING","2024-10-03",{"date":35,"type":36},"2024-10-08","ACTUAL",{"date":38,"type":36},"2022-08-03",{"date":40,"type":21},"2028-12",{"name":42,"class":43},"Minneapolis Heart Institute Foundation","OTHER"]